# Base editing cuts toxic protein 84% in AATD trial, FDA backs accelerated approval - Date: 2026-03-25 - Category: Biotech & Life Sciences For people living with alpha-1 antitrypsin deficiency, the disease is a slow-motion double insult: the lungs erode without protection, and the liver accumulates a misfolded protein it cannot clear. ---